Department of Biochemistry, Faculty of Science, The M.S. University of Baroda, Vadodara Gujarat, 390 002, India.
Evid Based Complement Alternat Med. 2013;2013:280392. doi: 10.1155/2013/280392. Epub 2013 Apr 15.
Aim. Stem cell therapy is one of the upcoming therapies for the treatment of diabetes. Discovery of potent differentiating agents is a prerequisite for increasing islet mass. The present study is an attempt to screen the potential of novel small biomolecules for their differentiating property into pancreatic islet cells using NIH3T3, as representative of extra pancreatic stem cells/progenitors. Methods. To identify new agents that stimulate islet differentiation, we screened various compounds isolated from Enicostemma littorale using NIH3T3 cells and morphological changes were observed. Characterization was performed by semiquantitative RT-PCR, Q-PCR, immunocytochemistry, immunoblotting, and insulin secretion assay for functional response in newly generated islet-like cell clusters (ILCC). Reversal of hyperglycemia was monitored after transplanting ILCC in STZ-induced diabetic mice. Results. Among various compounds tested, swertisin, an isolated flavonoid, was the most effective in differentiating NIH3T3 into endocrine cells. Swertisin efficiently changed the morphology of NIH3T3 cells from fibroblastic to round aggregate cell cluster in huge numbers. Dithizone (DTZ) stain primarily confirmed differentiation and gene expression studies signified rapid onset of differentiation signaling cascade in swertisin-induced ILCC. Molecular imaging and immunoblotting further confirmed presence of islet specific proteins. Moreover, glucose induced insulin release (in vitro) and decreased fasting blood glucose (FBG) (in vivo) in transplanted diabetic BALB/c mice depicted functional maturity of ILCC. Insulin and glucagon expression in excised islet grafts illustrated survival and functional integrity. Conclusions. Rapid induction for islet differentiation by swertisin, a novel herbal biomolecule, provides low cost and readily available differentiating agent that can be translated as a therapeutic tool for effective treatment in diabetes.
干细胞治疗是治疗糖尿病的新兴疗法之一。发现有效的分化剂是增加胰岛质量的前提。本研究旨在使用 NIH3T3(作为胰腺外干细胞/祖细胞的代表)筛选新型小分子生物的潜在分化特性。
为了鉴定刺激胰岛分化的新药物,我们使用 NIH3T3 细胞筛选了从益智中分离出的各种化合物,并观察形态变化。通过半定量 RT-PCR、Q-PCR、免疫细胞化学、免疫印迹和新生成的胰岛样细胞簇(ILCC)的功能反应胰岛素分泌测定来进行特性分析。在 STZ 诱导的糖尿病小鼠中移植 ILCC 后,监测血糖逆转情况。
在所测试的各种化合物中,分离出的黄酮类化合物 swertisin 最有效地将 NIH3T3 分化为内分泌细胞。Swertisin 可有效将 NIH3T3 细胞的形态从成纤维细胞转变为大量圆形聚集细胞簇。二硫嗪(DTZ)染色主要证实了分化,基因表达研究表明,swertisin 诱导的 ILCC 中快速启动了分化信号级联反应。分子成像和免疫印迹进一步证实了胰岛特异性蛋白的存在。此外,在移植的糖尿病 BALB/c 小鼠中,葡萄糖诱导的胰岛素释放(体外)和空腹血糖(FBG)降低(体内)表明了 ILCC 的功能成熟。从切除的胰岛移植物中检测到胰岛素和胰高血糖素的表达,表明了其存活和功能完整性。
新型植物生物小分子 swertisin 可快速诱导胰岛分化,为糖尿病的有效治疗提供了低成本、易于获得的分化剂,可作为一种治疗工具。